# A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

> **NCT06585969** · PHASE3 · WITHDRAWN · sponsor: **Danish Breast Cancer Cooperative Group**

## Conditions studied

- Metastatic Breast Cancer
- ER-positive Breast Cancer
- Luminal B
- Her2 Enriched
- Basal Like

## Interventions

- **DRUG:** Trastuzumab deruxtecan (T-DXd)
- **DRUG:** Ribociclib with ET
- **DRUG:** Abemaciclib with ET

## Key facts

- **NCT ID:** NCT06585969
- **Lead sponsor:** Danish Breast Cancer Cooperative Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-01-01
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-01-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06585969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06585969, "A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06585969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*